BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 17 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Delisting Notice: BrainStorm Cell Therapeutics received a Nasdaq delisting notice due to non-compliance with equity requirements, with trading suspended on July 18, 2025.
OTCQB Trading: The company has secured approval to trade on the OTCQB Venture Market under the same symbol "BCLI," starting on the same date as the Nasdaq suspension.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
